China Pharma Holdings (CPHI) Cash & Current Investments (2010 - 2026)
China Pharma Holdings' (CPHI) quarterly Cash & Current Investments came in at $304874.0 in Q2 2026, down 51.22% on a YoY basis from $625032.0 in Q2 2025, and up 79.34% quarter-over-quarter from $170000.0 in Q1 2026.
Analysis
China Pharma Holdings (CPHI) Cash & Current Investments (2010 - 2026) Analysis & Trends
China Pharma Holdings (CPHI) has reported Cash & Current Investments for 17 consecutive years, with $304874.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Cash & Current Investments fell 51.22% year-over-year to $304874.0; the trailing twelve-month figure through Jun 2026 stood at $304874.0 (down 51.22% YoY), and the FY2025 full-year result was $345112.0, down 44.95% from the prior year.
- Cash & Current Investments improved to $304874.0 in Q2 2026 per CPHI's latest filing, from $170000.0 in the prior quarter.
- Across five years, Cash & Current Investments topped out at $3.7 million in Q1 2022 and bottomed at $170000.0 in Q1 2026.
- Historically, Cash & Current Investments has averaged $1.1 million across 5 years, with a median of $789109.0 in 2024.
- The sharpest annual moves came in 2022 and 2023: Cash & Current Investments surged 594.97% in 2022, then tumbled 68.59% in 2023.
- Over 5 years, Cash & Current Investments stood at $2.0 million in 2022, then decreased by 29.86% to $1.4 million in 2023, then plunged by 55.97% to $626879.0 in 2024, then plunged by 44.95% to $345112.0 in 2025, then dropped by 11.66% to $304874.0 in 2026.
- According to Business Quant data, Cash & Current Investments over the past three periods registered $304874.0, $170000.0, and $345112.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 20.76 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 6.57 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 7.14 Bn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | 7.69 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 11.70 Bn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | 7.38 Bn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 4.54 Bn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 2.66 Bn |
| 10 | China Pharma Holdings | 31.39 Mn | 31.08 Mn | 83,566.00 | 304,874.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 304,874.00 |
| Mar 31, 2026 | 170,000.00 |
| Dec 31, 2025 | 345,112.00 |
| Sep 30, 2025 | 300,000.00 |
| Jun 30, 2025 | 625,032.00 |
| Mar 31, 2025 | 412,688.00 |
| Dec 31, 2024 | 626,879.00 |
| Sep 30, 2024 | 718,691.00 |
| Jun 30, 2024 | 739,337.00 |
| Mar 31, 2024 | 838,881.00 |
| Dec 31, 2023 | 1.42 Mn |
| Sep 30, 2023 | 1.37 Mn |
| Jun 30, 2023 | 901,910.00 |
| Mar 31, 2023 | 1.17 Mn |
| Dec 31, 2022 | 2.03 Mn |
| Sep 30, 2022 | 2.10 Mn |
| Jun 30, 2022 | 2.24 Mn |
| Mar 31, 2022 | 3.71 Mn |
| Dec 31, 2021 | 4.86 Mn |
| Sep 30, 2021 | 500,000.00 |